01
Cross the blood-brain barrier
Many promising small molecules never reach the brain. Our oral lipid nanoparticle carried one that couldn’t, EGCG, into the brain in preclinical studies. The same approach may work for yours.
Partnering
Partner with Adjuvia
Our lipid nanoparticle (LNP) platform addresses two of the hardest problems in drug development: getting molecules into the brain, and the inflammation that limits LNP, vaccine and immunotherapy medicines.
We work with
For your molecule
What our platform can do for your program
02
Take the inflammation out of delivery
Our astaxanthin can be built into lipid nanoparticles, or given alongside adjuvants and immunotherapies, to block harmful inflammatory signaling while the payload still gets through.
Available now
Programs ready for a partner
Preclinical proof of concept is complete. Full data packages are available under confidentiality.
Beyond rare diseases
More opportunities with ATI-105
ATI-105’s repair and anti-inflammatory activity may apply to common chronic diseases. We aren’t developing these indications ourselves, and we welcome partners who are.
How it works
How we work with partners
01
Introductory conversation
Tell us about your program and what you need from a delivery or anti-inflammatory solution.
02
Confidential data review
Under a confidentiality agreement, we share the full data package for the relevant program.
03
Collaboration or license
Co-development, co-formulation or licensing, structured around your program.
